CVS Health gave investors a pleasant surprise on Wednesday, lifting its profit outlook for 2026 after a second quarter that came in stronger than Wall Street expected. The key driver: medical costs at its Aetna insurance arm were lower than feared, easing concerns that had weighed on the stock.
The company now expects adjusted earnings of $7.90 to $8.10 per share for 2026, up from its previous forecast of $7.30 to $7.50. The upgrade follows a second-quarter adjusted profit of $2.58 per share, which blew past the $1.85 that analysts had penciled in, according to LSEG data.
What's behind the beat?
Revenue rose to $106.1 billion, also topping forecasts, as the company's pharmacy business showed improvement. CVS also benefited from bonus payments tied to its government-backed insurance plans, which earned high quality ratings.
But the number that investors zeroed in on was Aetna's medical loss ratio — the share of premiums that goes toward paying for members' medical care. That ratio came in at 87.4%, down from 89.9% a year ago. A lower ratio means the insurer is spending a smaller slice of premiums on claims, which typically signals healthier profit margins.
For context, the medical loss ratio is a closely watched metric in health insurance. If it climbs too high, it suggests costs are eating into profits. If it falls, as it did here, it often points to better-than-expected pricing or lower utilization of medical services.
Why this matters for investors
CVS has been under pressure for years as its Aetna unit struggled with rising medical costs, particularly in its Medicare Advantage plans. Those plans, which are privately run versions of Medicare, have been a drag on earnings across the industry as seniors use more services and as the government tightens reimbursement.
The better-than-expected quarter suggests that some of those pressures may be easing, at least for now. That could be a positive sign for the broader health insurance sector, which has been navigating similar headwinds.
For everyday investors, the key takeaway is that CVS is now projecting stronger profitability ahead. The company's diversified business — which includes pharmacies, pharmacy benefit management, and health insurance — gives it multiple revenue streams, but also makes it sensitive to shifts in drug pricing and healthcare utilization.
It's worth noting that the company's outlook is for 2026, which is a longer-term view than most quarterly updates. That suggests management is confident the improvement in medical costs isn't just a one-quarter blip.
What to watch next
Investors will likely keep a close eye on Aetna's medical loss ratio in coming quarters to see if the improvement holds. They'll also watch for any updates on Medicare Advantage reimbursement rates, which are set by the government and can significantly affect profitability.
CVS's results come amid a mixed earnings season for healthcare companies. Some, like Charles River Laboratories, have also raised their outlooks on improving demand, while others have struggled with cost pressures.
The company's upbeat report stands in contrast to some other recent earnings disappointments, such as Insulet's sales outlook cut and Uber's cautious Q3 guidance. It also echoes the optimism seen in Iron Mountain's raised outlook on AI-driven demand.
For CVS shareholders, the raised guidance is a welcome sign after a turbulent period. But as with any stock, it's important to remember that past performance doesn't guarantee future results. The company still faces long-term challenges, including competition in the pharmacy business and ongoing regulatory scrutiny of pharmacy benefit managers.
Still, for now, the market is rewarding CVS for delivering a quarter that beat expectations and for signaling that the worst of its medical cost troubles may be behind it.
